相关实验视频
Updated: May 16, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
71
在阿尔茨海默氏病的疾病阶段特定的缩标志物
Hannah Baumeister1, Helena M Gellersen1,2,3, Sarah E Polk1
1German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
medRxiv : the preprint server for health sciences
|March 31, 2025
概括
结构性MRI可以检测早期的阿尔茨海默氏症 (AD) 缩. 将MRI读数定制为特定的疾病阶段和用例,优化了AD的诊断和预后价值.
科学领域:
- 神经成像是一种神经成像.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 结构性MRI在早期阿尔茨海默氏症 (AD) 中具有有限的诊断效用.
- 提高MRI的诊断,预后和AD监测的价值至关重要.
研究的目的:
- 在阿尔茨海默病的各种应用中确定最佳的MRI读数.
- 在AD的不同阶段增强结构性MRI的实用性.
主要方法:
- 包括363名老年人:健康对照 (粉样蛋白β负/阳性) 和粉样蛋白β阳性认知能力下降的个体.
- 每年进行MRI和神经心理评估,长达三年.
主要成果:
- 在临床前AD期间观察到中部叶 (MTL) 亚区域的加速缩.
- 明显的海马和形缩模式标志着症状性AD阶段.
- 缩标志物与认知评分的关联因疾病阶段和预期用途而异.
结论:
- 核磁共振可以检测在临床前AD异常缩与适当的读数.
- 根据目标疾病阶段和用例定制MRI读数,对于优化性能至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133